Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Dupixent Legal and Medical Information About T-cell Lymphoma

October 8, 2025 By Law Offices of Thomas J. Lamb, P.A.

In this brief article, we present important Dupixent legal and medical information about T-cell lymphoma, which appears to be a Dupixent-related side effect. We start with some of the allegations contained in the lawsuits being filed against the pharmaceutical companies Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, based on … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cutaneous T-cell lymphoma (CTCL), Dupixent, mycosis fungoides, peripheral T-cell lymphoma (PTCL), Sézary syndrome, T-cell lymphoma

Dupixent Cancer Lawsuits: Legal and Medical Update

October 1, 2025 By Law Offices of Thomas J. Lamb, P.A.

We are currently investigating possible Dupixent cancer lawsuits for patients who were diagnosed with a type of cutaneous T-cell lymphoma (CTCL), such as mycosis fungoides (MF) or Sézary syndrome, after they started using Dupixent. The Dupixent cancer lawsuits would be filed against the manufacturers of Dupixent, Sanofi and Regeneron, based on … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cutaneous T-cell lymphoma (CTCL), Dupixent

Increased Risk of NAION Associated With Ozempic and Mounjaro

August 18, 2025 By Law Offices of Thomas J. Lamb, P.A.

A 2025 medical study concluded that there is an increased risk of NAION associated with Ozempic and Mounjaro.  In more detail, the researchers considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Mounjaro, Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic

NAION With Mounjaro and Zepbound Being Investigated

July 2, 2025 By Law Offices of Thomas J. Lamb, P.A.

The FDA is investigating the possible connection of NAION with Mounjaro and Zepbound, according to “October – December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)”. During the past year, we have written about the vision loss side effect NAION (non-arteritic … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Mounjaro, Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), vision loss, Zepbound

Semaglutide NAION Side Effect Can Be Part of a Vision Loss AION Diagnosis

June 11, 2025 By Law Offices of Thomas J. Lamb, P.A.

The European Medicines Agency (EMA) confirmed the link between the active ingredient in Ozempic, semaglutide, and NAION (non-arteritic anterior ischemic optic neuropathy) in early June 2025. This drug regulator said further that a semaglutide NAION side effect warning would be added to the drug labels for the semaglutide-containing drugs Wegovy, … [Read more...]

Filed Under: Uncategorized, Unsafe Drugs Tagged With: Anterior Ischemic Optic Neuropathy (AION), Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, semaglutide-containing drugs, vision loss, Wegovy

Ozempic Vision Loss Lawsuits Against Novo Nordisk

May 6, 2025 By Law Offices of Thomas J. Lamb, P.A.

Patients who are filing Ozempic vision loss lawsuits against Novo Nordisk had developed nonarteritic anterior ischemic optic neuropathy (NAION) while using Ozempic. These cases are product liability failure to warn lawsuits filed against the responsible drug company, Novo Nordisk, because the Ozempic drug label does not warn about NAION as a … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, vision loss, Wegovy

Vision Loss Linked to Rybelsus and Ozempic Use by Diabetes Patients

April 15, 2025 By Law Offices of Thomas J. Lamb, P.A.

The relatively new drug safety issue of vision loss linked to Rybelsus and Ozempic was the subject of a recent medical study that had this stated Objective, or purpose: “To investigate the association between semaglutide use and the risk of NAION among patients with diabetes.” On March 27, 2025, the JAMA Ophthalmology medical journal published … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, vision loss

Semaglutide: Eyesight Loss From Drug Side Effect NAION

February 26, 2025 By Law Offices of Thomas J. Lamb, P.A.

Semaglutide eyesight loss from the drug side effect NAION is being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company for Ozempic, Wegovy, and Rybelsus.  The active ingredient for each of those three Novo Nordisk drugs is semaglutide. There are a couple of recent … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, Wegovy

Depo-Provera Meningioma Increased Risk Warning in Europe

February 11, 2025 By Law Offices of Thomas J. Lamb, P.A.

The European Medicines Agency (EMA) recommended a Depo-Provera meningioma increased risk warning in September 2024. One wonders why the FDA has not followed this EMA regulatory action. Therefore, the Depo-Provera drug label in the US still does not include a warning about the meningioma increased risk associated with Depo-Provera. The following … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Depo-Provera, intracranial meningioma

Why Are There Depo-Provera Brain Tumor Warnings In Europe But Not US?

February 3, 2025 By Law Offices of Thomas J. Lamb, P.A.

Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma, a specific type of brain tumor, are being filed against the responsible pharmaceutical companies. A primary focus of these legal cases will be why the Depo-Provera drug label in the US does not include any warnings about the increased risk of this … [Read more...]

Filed Under: Unsafe Drugs Tagged With: brain tumors, Depo-Provera, intracranial meningioma

  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call 910-256-2971 to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

910-256-2971

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.